These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34667923)

  • 41. Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real-world, multicenter, retrospective study.
    Matino D; Iorio A; Keepanasseril A; Germini F; Caillaud A; Carcao M; Hews-Girard J; Iserman E; James P; Lee A; Phua CW; Sun HL; Teitel J; Poon MC
    Res Pract Thromb Haemost; 2022 Mar; 6(3):e12661. PubMed ID: 35386274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies.
    Chowdary P; Holmström M; Mahlangu JN; Ozelo MC; Pabinger I; Pasi KJ; Ragni MV; Shapiro A; Barnowski C; Lethagen S
    Res Pract Thromb Haemost; 2022 Jul; 6(5):e12760. PubMed ID: 35910942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys.
    Burke T; Asghar S; O'Hara J; Sawyer EK; Li N
    Orphanet J Rare Dis; 2021 Mar; 16(1):143. PubMed ID: 33743752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update.
    Aiello A; Mancuso ME; Leone S; Rossi L; Cioni L; Teruzzi C
    Glob Reg Health Technol Assess; 2022; 9():9-13. PubMed ID: 36628322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B.
    Aiello A; Mancuso ME; Colombo A; Teruzzi C; Berto P
    Glob Reg Health Technol Assess; 2020; 7():40-49. PubMed ID: 36627960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. No difference in quality of life between persons with severe haemophilia A and B.
    Kihlberg K; Baghaei F; Bruzelius M; Funding E; Andre Holme P; Lassila R; Nummi V; Ranta S; Gretenkort Andersson N; Berntorp E; Astermark J
    Haemophilia; 2023 Jul; 29(4):987-996. PubMed ID: 36791275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A single-centre study.
    Sinegre T; Trayaud A; Tardieu M; Fourneyron V; Talon L; Berger MG; Tillier M; Senectaire S; Gembara P; Barbin AL; Vaissade A; Lebreton A
    Haemophilia; 2020 May; 26(3):543-552. PubMed ID: 32314511
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.
    Windyga J; Lin VW; Epstein JD; Ito D; Xiong Y; Abbuehl BE; Ramirez JH
    Haemophilia; 2014 May; 20(3):362-8. PubMed ID: 24251442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity.
    Sommer JM; Buyue Y; Bardan S; Peters RT; Jiang H; Kamphaus GD; Gray E; Pierce GF
    Thromb Haemost; 2014 Nov; 112(5):932-40. PubMed ID: 25144892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.
    Buckner TW; Wang M; Cooper DL; Iyer NN; Kempton CL
    Patient Prefer Adherence; 2017; 11():1745-1753. PubMed ID: 29066870
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
    Chowdary P; Kearney S; Regnault A; Hoxer CS; Yee DL
    Haemophilia; 2016 Jul; 22(4):e267-74. PubMed ID: 27352908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.
    Chai-Adisaksopha C; Nevitt SJ; Simpson ML; Janbain M; Konkle BA
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011441. PubMed ID: 28944952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe.
    Burke T; Asghar S; O'Hara J; Chuang M; Sawyer EK; Li N
    Orphanet J Rare Dis; 2021 Dec; 16(1):521. PubMed ID: 34930388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein.
    McCue J; Osborne D; Dumont J; Peters R; Mei B; Pierce GF; Kobayashi K; Euwart D
    Haemophilia; 2014 Jul; 20(4):e327-35. PubMed ID: 24811361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre.
    Iyar S; Gebremariam GT; Beyene DA; Gebremedhin A; Tadesse TA
    J Pharm Health Care Sci; 2024 Jan; 10(1):3. PubMed ID: 38167221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
    Sommer JM; Sadeghi-Khomami A; Barnowski C; Wikén M; Willemze AJ
    Int J Lab Hematol; 2020 Jun; 42(3):350-358. PubMed ID: 32202380
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.
    Batt K; Recht M; Cooper DL; Iyer NN; Kempton CL
    Patient Prefer Adherence; 2017; 11():1369-1380. PubMed ID: 28860720
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.